Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis  by de Ávila, Renata Eliane et al.
O
R
IG
IN
A
L 
 
A
R
TI
CL
E
335
Hyaluronic acid in the evaluation of liver fibrosis 
in patients with hepatitis C on haemodialysis
Authors
Renata Eliane de Ávila1
Ricardo Andrade Carmo2 
Kátia de Paula Farah3
Antônio Lúcio Teixeira3
Lucas Viana Coimbra3
Carlos Maurício de 
Figueiredo Antunes4
José Roberto 
Lambertucci1
1Infectious Diseases Branch, 
Department of Internal 
Medicine, Faculdade de 
Medicina, Universidade 
Federal de Minas Gerais; 
Núcleo de Ações e Pesquisa 
em Apoio - NUPAD/ FM 
/ UFMG.
2Fundação Hemominas.
3Infectious Diseases Branch, 
Department of Internal 
Medicine, Faculdade de 
Medicina, Universidade 
Federal de Minas Gerais.
4Department of 
Parasitology, Instituto 
de Ciências Biológicas – 
UFMG.
Submitted on: 08/12/2009
Approved on: 11/18/2009
Correspondence to:
Dr. José Roberto 
Lambertucci
Faculdade de Medicina da 
UFMG
Departamento de Clínica 
Médica
Avenida Alfredo Balena,
190. Belo Horizonte - 
Minas Gerais - Brazil
CEP: 30130-100
Phone: +55-31-34099820
E-mail:
lamber@uai.com.br
This work was partially 
supported by Fundação 
de Amparo à Pesquisa 
do Estado de Minas 
Gerais (FAPEMIG) 
and Conselho Nacional 
de Desenvolvimento 
Científi co e Tecnológico 
(CNPq).
ABSTRACT
Background: This study evaluated the role of HA as a marker of liver fi brosis in patients with hepa-
titis C on haemodialysis. Methods: This is a cross-sectional study in which 52 patients were divided 
into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing 
haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels 
of HA were associated with histological data of the samples obtained by liver biopsy and classifi ed by 
METAVIR group scoring system. Results: Higher plasma levels were signifi cantly correlated to sig-
nifi cant liver fi brosis (METAVIR ≥ F2). In Group 1, the HA cutoff to discriminate signifi cant fi brosis 
was 984.8 ng/mL, with accuracy, sensitivity and specifi city of 80.8%, 83.0%, and 70.0%, respectively. 
In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specifi city of 74.5%, 
70.0%, and 94.0%, respectively. Conclusion: HA was an accurate noninvasive marker in predicting 
signifi cant fi brosis in patients with hepatitis C on haemodialysis.
Keywords: liver fi brosis, hyaluronic acid, end-stage renal disease, haemodialysis, hepatitis C.
[Braz J Infect Dis 2010;14(4):335-341]©Elsevier Editora Ltda.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection 
is common in patients on haemodialysis 
(HD) and has been associated with chronic 
liver disease in this setting. The prevalence 
of HCV infection in HD units ranges, ac-
cording to geographical area, from 9% to 
80% worldwide.1 In Brazil, several dialysis 
centers2-4 reported rates from 11% to 52%. 
The transfusion-associated transmissions 
have been reduced due to the implementa-
tion of blood donor screening for hepatitis 
C in the early 1990s and the use of recom-
binant erythropoietin. Currently, nosoco-
mial transmission is the main cause of HCV 
infection in this population.5,6 
The mortality rate of HCV infected 
HD patients is higher than non-infected 
subjects.7,8 Candidates for renal transplanta-
tion have to be treated for hepatitis C before 
surgery, since HCV infection has a negative 
impact on graft and patient survival.9 The 
degree of fibrosis evaluation is paramount 
for treatment decision.
Liver biopsy remains the gold stand-
ard procedure for diagnosing liver fibrosis. 
However, it is an invasive method associated 
with sampling error, interobserver variabil-
ity and potential complications.10 In HD pa-
tients, the rate of complications is elevated 
due to higher risk of bleeding secondary to 
haemostatic disorders.11,12 In a recent study, 
severe complications of liver biopsies were 
demonstrated in 13.2% of HD patients.13 
Therefore, there is a need to assess the util-
ity of noninvasive markers of fibrosis in this 
population.
Hyaluronic acid (HA) has been used to 
predict liver fibrosis in patients with chronic 
hepatitis C.14-17 APRI (aspartate-aminotrans-
ferase to platelet ratio index) is another 
promising liver fibrosis marker in hepatitis 
C.18-20 In a recent study, APRI identified sig-
nificant liver fibrosis (METAVIR ≥ F2) with 
accuracy of 80.1% in patients with hepatitis 
C on haemodialysis.21
However, the value of HA in the diagnosis 
of liver fibrosis in this population with HCV 
infection has yet to be defined. The aim of 
this study was to evaluate the role of HA as 
a noninvasive marker of fibrosis in patients 
with chronic hepatitis C on haemodialysis.
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PATIENTS AND METHODS
This is a cross-sectional study of patients attending an 
Infectious Diseases Outpatient Clinic and Haemodialy-
sis Unit at the Hospital of the Universidade Federal de 
Minas Gerais-HC-UFMG (Belo Horizonte, Brazil). 
Patients with chronic hepatitis C and end-stage renal 
disease (ESRD) on haemodialysis are referred to our out-
patient clinic to be evaluated and treated for hepatitis C. 
Our current practice is to treat hepatitis C according to 
the degree of fibrosis found in liver fragments obtained 
by needle liver biopsy. From May 2000 to October 2007, 
69 patients with chronic hepatitis C and ESRD on HD 
who underwent liver biopsy in a previous study13 were 
registered under our care. Among those subjects, all in-
dividuals who had stored plasma sample (used in HCV-
RNA detection) and liver fragments collected within 
one year by liver biopsy were considered for enrollment. 
These patients were selected for group 1 (hepatitis C and 
ESRD on HD). The other 67 consecutive patients with 
chronic hepatitis C without ESRD who had undergone 
liver biopsy for treatment evaluation and collection 
of plasma sample were also considered for enrollment 
(group 2). 
The study was approved by the Ethics Committee of 
Universidade Federal de Minas Gerais (Belo Horizonte, 
MG, Brazil). A written informed consent was obtained 
from each participant prior to commencement of the 
study.
Criteria for selection of subjects
The inclusion criteria for subjects of groups 1 and 2 
were availability of liver fragments obtained by liver 
biopsy and a plasma sample collected within one year; 
age between 18 and 70 years old; presence of chronic 
HCV infection (defined as a reactive anti-HCV antibod-
ies for more than six months and a positive HCV-RNA 
by PCR); absence of other chronic liver diseases such as 
hepatitis B (defined as negative reaction to HBV sur-
face antigen and HBV core antibody), auto-immune 
hepatitis (negative reaction to antinuclear, anti-smooth 
muscle, anti-mitochondrial and anti-liver-kidney mi-
crosomal antibodies), schistosomiasis mansoni (no pre-
vious history and negative stool examination), negative 
reaction to anti-HIV-1/2 (EIA); no previous history of 
regular use of hepatotoxic drugs or alcohol abuse (> 40 
g of alcohol/day). Patients previously treated for hepati-
tis C were excluded.
Socio-demographic, epidemiological 
and clinical data
Baseline data were collected at the time of liver biopsy 
(in Groups 1 and 2) including: age, gender and length of 
time under haemodialysis (in group 1). 
Laboratory data
Levels of aminotransferases (alanina-aminotransferase-
ALT and aspartate-aminotransferase-AST), hemoglob-
in, platelets, and albumin were collected at the time of 
liver biopsy in groups 1 and 2. Parathormone (PTH) was 
measured in group 1. 
Assay for anti-HCV antibodies was determined us-
ing enzyme immunoassay EIA III (Abbot Laboratories, 
North Chicago, IL, USA). For RNA extraction, blood 
HCV-RNA was detected by transcription followed by 
nested-RT-PCR using primers derived from the 5’-UTR 
non-coding region of the HCV. The genotype was deter-
mined through Restriction Fragment Length Polymor-
phism (RFLP) analysis of the PCR product.
Histological analyses
Liver samples were obtained by percutaneous ultrasound-
directed hepatic biopsy. Two experienced pathologists ex-
amined (reviewed) liver fragments in a blinded manner 
(they knew the patients had hepatitis C but did not have 
any information about their clinical statuses). After disclo-
sure of the diagnosis, the discordant cases were re-analyzed 
and a consensus was reached. The histological samples were 
analyzed using the METAVIR algorithm:22 F0 = no fi brosis, 
F1 = portal fi brosis without septa, F2 = few septa, F3 = nu-
merous septa without cirrhosis, and F4 = cirrhosis. Stages 
of fi brosis were categorized as signifi cant fi brosis (META-
VIR ≥ F2) and absent or mild fi brosis (METAVIR < F2).
Plasma hyaluronic acid assay
HA plasma levels were assessed by a quantitative en-
zyme-linked antibody (HA-ELISA) and colorimetric 
detection with a commercially available test Kit (Ech-
elon Biosciences®, Salt Lake City, USA). For this test, HA 
normal value was < 50 ng/mL.
Statistical analyses
Descriptive analyses were performed to determine the fre-
quency of the categorical variables and the central tenden-
cies of the continuous variables. Continuous variables were 
compared using the Students t test, or Kruskal-Wallis, as 
appropriate comparisons of groups. Categorical variables 
were compared using Chi-square or Fishers exact test. The 
relationships between HA levels and fi brosis stages were 
established using the Mann-Whitney test. Logarithmic 
transformation was used for HA levels. The accuracy of 
HA to predict the presence or absence of signifi cant fi brosis 
(METAVIR ≥ F2) was tested by measuring the area under the 
receiver operating characteristic curve (AUROC). The best 
cutoff point was determined based on this curve. A p-value 
of less than 0.05 was considered statistically signifi cant. Sta-
tistical analysis was performed by SPSS software version 12.0 
(SPSS Inc., Chicago, IL). 
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RESULTS
Socio-demographic, clinical and laboratory 
characteristics
Socio-demographic, clinical and laboratory features of the 
patients are shown in Table 1.
A total of 136 patients were considered for enrollment in 
groups 1 and 2. However, the plasma samples were not col-
lected within one year of liver biopsy in 20 and 12 in groups 
1 and 2 patients, respectively. Other 22 patients of group 
1 were not included because of the following reasons: age 
< 18 or > 70 years (n = 2), schistosomiasis (n = 7), hepatitis B 
(n = 3), use of hepatotoxic drugs (n = 6), and auto-immune 
hepatitis (n = 1). In group 2, 26 patients were not included 
because of the following fi ndings: age < 18 or > 70 years 
(n = 2), schistosomiasis (n = 4), alcohol abuse (n = 8), use 
of hepatotoxic drugs (n = 4), hepatitis B (n = 4), previously 
treated for hepatitis C (n = 4). 
Baseline characteristics (age, gender and time on haemo-
dialysis in group 1) of patients who were excluded due to 
unavailable plasma sample collected at least one year of liver 
biopsy were compared to the characteristics of the included 
participants in groups 1 and 2. In group 1, excluded patients 
were signifi cantly older than those included (p = 0.01), 
whereas in group 2 no difference was observed between in-
cluded and excluded patients.
A total of 52 patients have been selected for this study: 
group 1 (Hepatitis C and ESRD, n = 23) and group 2 (Hepa-
titis C and no ESRD, n = 29).
The two groups were similar regarding age and gender. 
None of the included patients had clinical manifestations of 
liver failure. There was a predominance of genotype 1, be-
ing of 95.7% in group 1 and of 79.0% in group 2. ALT and 
AST levels were signifi cantly lower in patients with hepatitis 
C and ESRD , when compared to patients without ESRD. 
These patients also had a lower level of albumin and hemo-
globin (Table 1).
Table 1. Distribution of socio-demographic, clinical and laboratory features of 52 patients included in groups 1 
(hepatitis C and end-stage renal disease) and 2 (hepatitis C alone)
Characteristics Group 1 Group 2
  (Hepatitis C and ESRD) (Hepatits C alone) p-value*
   n = 23 n = 29
Age (mean ± SD years) 43.47 (± 12.37)  46.07 (± 12.39) 0.74
Gender
 Male n (%) 11 (48.1) 18 (62.1) 0.45
 Female n (%) 12 (51.9) 11 (37.9) -
Skin color
 White n (%) 07 (30.4) 13 (44.8) -
 Black n (%) 05 (21.7) 01 (3.4) 0.67
 Others n (%) 11 (47.8) 15 (51.7) -
Time of haemodialysis 9.67 ± 5.00 - -
(years, mean ± SD)
ALT** (U/L median) 37.0 74.0 0.00
AST*** (U/L median) 29.0 53.3 0.00
Haemoglobin (g/dL median) 11.5 15.6 0.00
Platelets (/mm3 median) 194,000 212,000 0.51
Albumin (g/dL median) 3.7 4.3 0.00
PTH**** (pg/L mean) 381.04 - -
*Student t test, Fishers exact test, Chi-square test, as appropriate comparisons of groups. 
**ALT: alanine-aminotransferase.
***AST: aspartate-aminotransferase.
****PTH: Parathormone (normal value: below 69 pg/L).
338
Histological data
The mean number of portal tracts in the biopsies was 9 
in both groups. Steatosis was observed in 55.2% of group 
2 patients, and hepatic siderosis in 56.5% of group 1 sub-
jects. Histological examination revealed signifi cant fi brosis 
in 56.5% in patients of group 1 and in 44.3% in group 2. 
However, the frequency of advanced fi brosis and cirrhosis 
(METAVIR ≥ F3) was low in both groups (Figure 1).
Table 2. Hyaluronic acid levels in groups 1 (hepatitis C and end-stage renal disease) and 2 (hepatitis C alone)
  Hyaluronic acid (ng/mL)
Study groups n Mean Median Minimal Maximum SD p-value*
1 (ESRD**/hepatitis C) 23 5002.8 1546.3 302.5 3922.3 9455.9 0.00
2 (Hepatitis C) 29 268.3 160.8 80.9 1029.3 255.3 -
*Kruskal-Wallis.
** ESRD: end-stage renal disease.
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Figure 1: Frequency distribution of histological fibrosis stage according to the METAVIR score in 23 patients with end-stage renal 
disease (ESRD) and hepatitis C (group 1) and 29 patients with hepatitis C alone (group 2).
Figure 2: Box plot of logarithmic hyaluronic acid (HA) level in relation to study groups. There was significant difference between 
HA levels in groups 1 and 2 (p = 0.00).
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Variables associated with signiﬁ cant ﬁ brosis
Median of plasma HA levels in groups 1 and 2 were: 1546.3 
ng/mL and 160.8 ng/mL, respectively (p < 0.00) (Table 2; 
Figure 2). In group 1, higher plasma levels of HA were corre-
lated to signifi cant liver fi brosis: the median of HA was 822.1 
ng/mL in patients without signifi cant fi brosis (METAVIR < 
F2), and 3,402.6 ng/mL in patients with signifi cant fi bro-
sis (p = 0.01). In group 2, the median of HA plasma levels 
Hyaluronic acid in hepatitis C
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was 141.0 ng/mL in patients without signifi cant fi brosis and 
277.6 ng/mL in patients with signifi cant fi brosis (p = 0.02). 
In group 1, only HA levels were correlated with the de-
gree of liver fi brosis by METAVIR algorithm. There was no 
signifi cant association between age, gender, AST and ALT 
levels with degree of fi brosis. In group 2, HA and ALT lev-
els were signifi cantly associated with degree of liver fi brosis 
(Table 3).
In Group 1, the HA cutoff applied to discriminate sig-
nifi cant fi brosis was 984.8 ng/mL, with accuracy (AUROC), 
sensitivity and specifi city of 80.8%, 83.0%, and 70.0%, re-
spectively. In group 2, the HA cutoff was 222.3 ng/mL, with 
Table 3. Variables associated with the degree of liver fibrosis (absent or mild: METAVIR < F2 or significant: 
METAVIR ≥ F2, in groups 1 (hepatitis C and end-stage renal disease) and 2 (hepatitis C alone)
Variables  Group 1 (n = 23)   Group 2 (n = 29)
  METAVIR < F2 METAVIR ≥ F2 p-value METAVIR < F2 METAVIR ≥ F2 p-value
Gender 
 Male 3 (27.3%) 8 (72.8%) 0.21* 7 (38.9%) 11 (61.1%) 0.05*
 Female 7 (58.3%) 5 (41.7%) - 9 (81.8%) 2 (18.2%) -
Age (years)† 41.5 46.0 0.44** 44.0 47.0 0.66**
AST (U/L)†† 21.0 29.0 0.55** 44.0 49.0 0.07**
ALT (U/L)†† 35.0 36.0 0.83** 56.0 91.0 0.01**
Hyaluronic acid (ng/mL)† 822.1 3402.6 0.01** 141.0 277.6 0.02**
† Median ; †† Mean.
* Fisher’s exact test; ** Mann-Whitney test.
accuracy, sensitivity and specifi city of 74.5%, 70.0%, and 
94.0%, respectively (Figure 3).
Variables associated with plasma levels of 
hyaluronic acid in patients on hemodialysis
In group 1, only HA levels were correlated with the degree 
of liver fi brosis by METAVIR algorithm (p = 0.01). There 
was no signifi cant correlation among age, gender and time 
of haemodialysis in this group. Hyperparathyroidism (PTH 
> 69 pg/L) was found in 95.7% of group 1 patients, but there 
was no signifi cant correlation between serum parathormone 
(PTH) and HA levels.
Figure 3: Receiver operating characteristic curves of hyaluronic acid for the prediction of significant fibrosis (METAVIR ≥ F2). 
A: group 1 (patients with end-stage renal disease with hepatitis C). B: group 2 (Hepatitis C alone).
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DISCUSSION
In this study, plasma hyaluronic acid (HA) level was a good 
noninvasive marker of signifi cant fi brosis in patients with 
hepatitis C on haemodialysis. For hepatitis C without ESRD, 
our fi ndings are comparable to those reported previously.14-17 
For patients with ESRD, this is much more important than 
for patients with hepatitis C without co-morbidities. The 
frequency and severity of complications of liver biopsy in 
patients with renal failure has been documented.11-13 There-
fore, HA levels may be used to defi ne when treatment for 
hepatitis C should be considered, especially in subjects with 
coagulation dysfunction caused by renal failure. Besides, it 
may be used as a screening test before a decision in favor of 
liver biopsy is to be presented to the patient. 
Our fi ndings contrast with the observations of a recent 
study.22 In the latter, the diagnostic value of hyaluronic acid 
(HA) as a noninvasive marker of liver fi brosis was evaluated 
in 185 ESRD HCV-infected patients. For the prediction of 
signifi cant fi brosis, the AUROC (0.798) of the regression 
model, including AST, platelet count and HA, was signifi -
cantly higher than the AUROC of HA (0.650).
The specifi city of HA in detecting signifi cant liver fi bro-
sis was lower in group 1 than in group 2. It may result from 
other factors that increase HA levels in ESRD patients. High 
plasma levels of HA have already been described in ESRD.24-26 
The increase of plasmatic HA in ESRD has been attributed 
to an “inﬂ ammatory state” caused by haemodialysis itself.24 
Notwithstanding, as observed for patients in group 1, plas-
ma HA levels reached even higher levels in the presence of 
hepatitis C infection, validating the test in the identifi cation 
of patients with signifi cant liver fi brosis.
Patients on haemodialysis usually develop second-
ary hyperparathyroidism and it was found in most group 
1 patients (Table 1). Parathyroid hormone (PTH) is a key 
hormone regulating bone mineral homeostasis and it also 
stimulates the production of HA in cultures of bone cells24, 
25 Nevertheless, in comparing PTH levels with HA levels in 
group 1 (13 patients with fi brosis and 10 without) no statis-
tical correlation was found (i.e. high HA levels were associ-
ated with liver fi brosis, but not with PTH values). Certainly, 
a larger number of patients should be evaluated to confi rm 
whether PTH, due to its action in bone metabolism, has any 
inﬂ uence in plasma HA levels. If HA is to be used alone as a 
marker of fi brosis, it may give a false positive test for fi brosis 
that may result in unnecessary and unwanted treatment for 
hepatitis C. 
In the present study, women with ESRD had lower levels 
of plasma HA. It has been shown that estrogen decreases os-
teoclast number, decreasing therefore bone resorption.26 Es-
trogen seems to regulate osteoclastogenesis by modulating 
cytokine production (interleukins 1 and 6 and tumor necro-
sis factor), and expression of adhesion molecules on bone 
marrow stromal cells. Sex steroids also act directly upon the 
parathyroid gland to increase PTH mRNA at physiological 
relevant doses.26 The decrease of bone metabolism in es-
trogen producing women may explain the decrease in HA 
liberation by bone cells and their lower levels in patients 
with ESRD.
The longer the patient stays on haemodialysis, probably 
the stronger is the inﬂ ammatory process associated with 
chronic haemodialysis. It has been previously reported 
that the timespan on haemodialysis and certain markers 
of chronic inﬂ ammation, such as dialysis-related amyloid, 
correlate to HA serum levels.16 Cytokine production may 
be stimulated by contact of the blood with bioincompat-
ible dialysis membranes, and cytokines have been shown 
to stimulate the synthesis of HA. The length of time on 
haemodialysis did not correlate to HA levels in our study, 
and the reason for that is uncertain. However, two factors 
should be considered: (1) 12 out of our 23 patients (52.2%) 
on haemodialysis were women and estrogen decreases HA 
serum levels; and (2) the mean time on haemodialysis in 
the present study was of 9.7 years and a signifi cant differ-
ence in HA levels can take more than 10 years to be de-
tected.
Older people tend to have a series of disadvantages on 
haemodialysis. As survival has increased with dialysis, they 
are usually those who have endured haemodialysis for long-
er periods (and consequently they have spent more time 
in an environment with persistent chronic inﬂ ammation), 
and the chronic inﬂ ammatory process caused by dialysis 
may result in decreased albumin synthesis by the liver as a 
result of cytokines stimulation of acute-phase reactants.21 
In addition, as sex steroids decrease with aging, they may 
increase osteoporosis and the levels of plasma HA.
However, no statistical correlation was found between 
age, gender and time on haemodialysis in group 1. This 
fi nding indicates that liver fi brosis was the main factor as-
sociated with the increase of HA serum levels in group 1 
patients. In addition, aminotransferase serum levels were 
not associated with liver fi brosis on haemodialysis patients 
with hepatitis C, as shown by others.25 
The number of patients studied and the low frequency 
of advanced fi brosis and cirrhosis (METAVIR ≥ F3) were 
the main limitations of this study. As a matter of fact, pa-
tients with decompensated liver cirrhosis are not referred 
to our outpatient clinic for therapeutic decision because 
such patients are not candidates for hepatitis C treatment 
before kidney transplantation.
Time has come to start using the best tests, so far prov-
en to be reliable, like HA levels, in the diagnosis of patients 
with hepatitis C on haemodialysis that are in need of treat-
ment, and to start conventional therapy to evaluate their 
performance as markers of fi brosis regression. In fact, a 
recent trial has been reported using hyaluronic acid in pa-
tients treated for hepatitis C with promising results.31
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In conclusion, plasma HA levels can predict the pres-
ence of signifi cant fi brosis in patients with hepatitis C on 
haemodialysis with good sensitivity and specifi city. It is 
desirable to start treatment for hepatitis C in this group 
of patients and to follow the behavior of hyaluronic acid 
levels after successful treatment to establish its value as a 
marker of fi brosis regression.
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